High Wire Networks announced its 2025 quarterly financial statements should no longer be relied upon after discovering it failed to record loan defaults, understating expenses and net loss by $1.4 million. The company also identified a material weakness in its internal controls over debt monitoring.
Nuvalent, Inc. has completed its merger with a subsidiary of GSK plc, with the tender offer closing at 91.3% of shares tendered.
Palmer Square Capital BDC completed a reset of its $300 million collateralized loan obligation, issuing new secured notes and extending the debt maturity to July 2039 while retaining all subordinated notes.
Regen BioPharma reached a court-approved settlement to resolve a $398,740 claim by issuing shares of its stock, and it replaced its independent auditor after that firm’s attest business was acquired.
Hawthorn Bancshares announced it has obtained all required regulatory approvals to complete its acquisition of FSC Bancshares, leaving only FBI shareholder approval and other customary closing conditions before the deal can close in the third quarter of 2026.
OFA Group’s annual report details that it recorded a $15 million tokenization services contract at zero value because the fair value of the noncash consideration received could not be reliably measured, while also confirming it has until December 7 to regain Nasdaq’s minimum bid price requirement.
SBC Medical Group Holdings disclosed it received a Nasdaq notice of non-compliance with board independence and audit committee requirements after director Mike Sayama did not stand for re-election.
Waste Energy Corp. disclosed in its annual report that its recurring losses and working capital deficit raise substantial doubt about its ability to continue as a going concern, while the company works toward commercial operations at its Midland, Texas facility later this year.
Diana Shipping extended the expiration of its unsolicited tender offer for Genco Shipping & Trading to July 24, 2026, and reported that 29.7% of shares not already owned by Diana have been tendered into the $27.34 per share cash-and-stock offer.
Cue Biopharma secured approximately $50 million through a private stock sale to fund clinical development, while its own forward-looking statement disclosures acknowledge the company still faces a going concern determination and may not have enough capital to operate beyond the next twelve months.
Record Alpha uses automated systems to identify and summarize public filings, court records, and regulatory actions as they become available. Every article links directly to the primary source document so readers can verify details firsthand. This content is for informational purposes only and is not investment, legal, or financial advice. Full disclaimer →
© 2026 Record Alpha. All rights reserved.